nodes	percent_of_prediction	percent_of_DWPC	metapath
Amiodarone—CYP2A6—esophageal cancer	0.48	0.729	CbGaD
Amiodarone—ABCB1—esophageal cancer	0.179	0.271	CbGaD
Amiodarone—THRB—neck—esophageal cancer	0.00255	0.0945	CbGeAlD
Amiodarone—THRA—neck—esophageal cancer	0.00255	0.0945	CbGeAlD
Amiodarone—CACNA2D2—neck—esophageal cancer	0.00253	0.0935	CbGeAlD
Amiodarone—CACNA1H—smooth muscle tissue—esophageal cancer	0.00134	0.0497	CbGeAlD
Amiodarone—THRB—lung—esophageal cancer	0.0011	0.0408	CbGeAlD
Amiodarone—THRA—lung—esophageal cancer	0.0011	0.0408	CbGeAlD
Amiodarone—CACNA2D2—lung—esophageal cancer	0.00109	0.0404	CbGeAlD
Amiodarone—Cognitive disorder—Methotrexate—esophageal cancer	0.00108	0.00676	CcSEcCtD
Amiodarone—Infection—Carboplatin—esophageal cancer	0.00103	0.00643	CcSEcCtD
Amiodarone—Liver injury—Cisplatin—esophageal cancer	0.00101	0.00633	CcSEcCtD
Amiodarone—Lung infiltration—Methotrexate—esophageal cancer	0.000998	0.00623	CcSEcCtD
Amiodarone—Hypothyroidism—Capecitabine—esophageal cancer	0.000979	0.00611	CcSEcCtD
Amiodarone—Extravasation—Cisplatin—esophageal cancer	0.000977	0.0061	CcSEcCtD
Amiodarone—Interstitial pneumonia—Methotrexate—esophageal cancer	0.000968	0.00605	CcSEcCtD
Amiodarone—Cellulitis—Cisplatin—esophageal cancer	0.000937	0.00586	CcSEcCtD
Amiodarone—Bone marrow depression—Capecitabine—esophageal cancer	0.000931	0.00581	CcSEcCtD
Amiodarone—Hypercalcaemia—Capecitabine—esophageal cancer	0.000904	0.00565	CcSEcCtD
Amiodarone—Torsade de pointes—Capecitabine—esophageal cancer	0.000896	0.0056	CcSEcCtD
Amiodarone—Hepatomegaly—Capecitabine—esophageal cancer	0.000888	0.00555	CcSEcCtD
Amiodarone—Pain—Carboplatin—esophageal cancer	0.000887	0.00554	CcSEcCtD
Amiodarone—Hepatocellular injury—Cisplatin—esophageal cancer	0.000852	0.00533	CcSEcCtD
Amiodarone—Haemoptysis—Capecitabine—esophageal cancer	0.000849	0.0053	CcSEcCtD
Amiodarone—Wheezing—Cisplatin—esophageal cancer	0.000828	0.00517	CcSEcCtD
Amiodarone—Ventricular fibrillation—Capecitabine—esophageal cancer	0.000821	0.00513	CcSEcCtD
Amiodarone—Pleural effusion—Capecitabine—esophageal cancer	0.000821	0.00513	CcSEcCtD
Amiodarone—Body temperature increased—Carboplatin—esophageal cancer	0.00082	0.00512	CcSEcCtD
Amiodarone—ADRB1—bronchus—esophageal cancer	0.000817	0.0302	CbGeAlD
Amiodarone—Skin exfoliation—Cisplatin—esophageal cancer	0.000814	0.00508	CcSEcCtD
Amiodarone—Neuropathy—Cisplatin—esophageal cancer	0.0008	0.005	CcSEcCtD
Amiodarone—SIGMAR1—bronchus—esophageal cancer	0.000784	0.029	CbGeAlD
Amiodarone—Myocardial ischaemia—Capecitabine—esophageal cancer	0.000782	0.00488	CcSEcCtD
Amiodarone—SIGMAR1—smooth muscle tissue—esophageal cancer	0.000767	0.0283	CbGeAlD
Amiodarone—Eruption—Methotrexate—esophageal cancer	0.00076	0.00475	CcSEcCtD
Amiodarone—THRA—lymph node—esophageal cancer	0.000755	0.0279	CbGeAlD
Amiodarone—THRB—lymph node—esophageal cancer	0.000755	0.0279	CbGeAlD
Amiodarone—CACNA2D2—lymph node—esophageal cancer	0.000748	0.0276	CbGeAlD
Amiodarone—Phlebitis—Cisplatin—esophageal cancer	0.000718	0.00449	CcSEcCtD
Amiodarone—SIGMAR1—trachea—esophageal cancer	0.000704	0.026	CbGeAlD
Amiodarone—Skin discolouration—Capecitabine—esophageal cancer	0.000696	0.00435	CcSEcCtD
Amiodarone—Bone marrow depression—Methotrexate—esophageal cancer	0.000693	0.00433	CcSEcCtD
Amiodarone—Cellulitis—Capecitabine—esophageal cancer	0.000691	0.00432	CcSEcCtD
Amiodarone—Liver disorder—Methotrexate—esophageal cancer	0.000686	0.00429	CcSEcCtD
Amiodarone—Haemolytic anaemia—Cisplatin—esophageal cancer	0.000685	0.00428	CcSEcCtD
Amiodarone—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000682	0.00426	CcSEcCtD
Amiodarone—Renal failure acute—Cisplatin—esophageal cancer	0.00067	0.00419	CcSEcCtD
Amiodarone—Interstitial lung disease—Methotrexate—esophageal cancer	0.000661	0.00413	CcSEcCtD
Amiodarone—Lung disorder—Methotrexate—esophageal cancer	0.000661	0.00413	CcSEcCtD
Amiodarone—CYP2A6—lung—esophageal cancer	0.000656	0.0242	CbGeAlD
Amiodarone—Inflammation—Capecitabine—esophageal cancer	0.000648	0.00405	CcSEcCtD
Amiodarone—Gait disturbance—Capecitabine—esophageal cancer	0.000644	0.00402	CcSEcCtD
Amiodarone—Coordination abnormal—Capecitabine—esophageal cancer	0.00064	0.004	CcSEcCtD
Amiodarone—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000639	0.00399	CcSEcCtD
Amiodarone—Injection site reaction—Capecitabine—esophageal cancer	0.000625	0.0039	CcSEcCtD
Amiodarone—Pleural effusion—Methotrexate—esophageal cancer	0.000611	0.00382	CcSEcCtD
Amiodarone—CACNA1H—lymph node—esophageal cancer	0.000606	0.0224	CbGeAlD
Amiodarone—Skin exfoliation—Capecitabine—esophageal cancer	0.0006	0.00375	CcSEcCtD
Amiodarone—Necrosis—Methotrexate—esophageal cancer	0.000596	0.00372	CcSEcCtD
Amiodarone—Neuropathy—Capecitabine—esophageal cancer	0.00059	0.00369	CcSEcCtD
Amiodarone—Dry eye—Capecitabine—esophageal cancer	0.00058	0.00363	CcSEcCtD
Amiodarone—Ecchymosis—Capecitabine—esophageal cancer	0.000568	0.00355	CcSEcCtD
Amiodarone—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000557	0.00348	CcSEcCtD
Amiodarone—Apnoea—Methotrexate—esophageal cancer	0.000552	0.00345	CcSEcCtD
Amiodarone—Extravasation—Methotrexate—esophageal cancer	0.000536	0.00335	CcSEcCtD
Amiodarone—CYP1A1—epithelium—esophageal cancer	0.000535	0.0198	CbGeAlD
Amiodarone—Phlebitis—Capecitabine—esophageal cancer	0.000529	0.00331	CcSEcCtD
Amiodarone—ADRB1—lung—esophageal cancer	0.000527	0.0195	CbGeAlD
Amiodarone—Thrombophlebitis—Capecitabine—esophageal cancer	0.000527	0.00329	CcSEcCtD
Amiodarone—Sleep disorder—Capecitabine—esophageal cancer	0.000527	0.00329	CcSEcCtD
Amiodarone—CYP1A1—bronchus—esophageal cancer	0.000527	0.0195	CbGeAlD
Amiodarone—Pancreatitis—Cisplatin—esophageal cancer	0.000524	0.00328	CcSEcCtD
Amiodarone—Hepatic function abnormal—Capecitabine—esophageal cancer	0.000522	0.00326	CcSEcCtD
Amiodarone—Photosensitivity—Capecitabine—esophageal cancer	0.000519	0.00325	CcSEcCtD
Amiodarone—Skin discolouration—Methotrexate—esophageal cancer	0.000518	0.00324	CcSEcCtD
Amiodarone—Pancytopenia—Cisplatin—esophageal cancer	0.000508	0.00317	CcSEcCtD
Amiodarone—Hepatic failure—Capecitabine—esophageal cancer	0.000508	0.00317	CcSEcCtD
Amiodarone—SIGMAR1—lung—esophageal cancer	0.000506	0.0187	CbGeAlD
Amiodarone—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000505	0.00316	CcSEcCtD
Amiodarone—CYP2C19—digestive system—esophageal cancer	0.000505	0.0187	CbGeAlD
Amiodarone—Renal failure acute—Capecitabine—esophageal cancer	0.000494	0.00309	CcSEcCtD
Amiodarone—Libido decreased—Capecitabine—esophageal cancer	0.000492	0.00307	CcSEcCtD
Amiodarone—Hot flush—Capecitabine—esophageal cancer	0.000488	0.00305	CcSEcCtD
Amiodarone—Menopausal symptoms—Capecitabine—esophageal cancer	0.000483	0.00302	CcSEcCtD
Amiodarone—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000483	0.00302	CcSEcCtD
Amiodarone—Inflammation—Methotrexate—esophageal cancer	0.000482	0.00301	CcSEcCtD
Amiodarone—Atrial fibrillation—Capecitabine—esophageal cancer	0.000481	0.00301	CcSEcCtD
Amiodarone—Renal impairment—Capecitabine—esophageal cancer	0.000479	0.00299	CcSEcCtD
Amiodarone—Vasculitis—Methotrexate—esophageal cancer	0.000479	0.00299	CcSEcCtD
Amiodarone—CYP1A1—trachea—esophageal cancer	0.000473	0.0175	CbGeAlD
Amiodarone—Renal failure—Cisplatin—esophageal cancer	0.000469	0.00293	CcSEcCtD
Amiodarone—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000467	0.00292	CcSEcCtD
Amiodarone—Cardiac failure—Capecitabine—esophageal cancer	0.000467	0.00292	CcSEcCtD
Amiodarone—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000453	0.00283	CcSEcCtD
Amiodarone—Skin exfoliation—Methotrexate—esophageal cancer	0.000447	0.00279	CcSEcCtD
Amiodarone—Aplastic anaemia—Methotrexate—esophageal cancer	0.000439	0.00274	CcSEcCtD
Amiodarone—Bradycardia—Cisplatin—esophageal cancer	0.000436	0.00272	CcSEcCtD
Amiodarone—Cardiac arrest—Capecitabine—esophageal cancer	0.000434	0.00271	CcSEcCtD
Amiodarone—Ataxia—Capecitabine—esophageal cancer	0.000429	0.00268	CcSEcCtD
Amiodarone—Ecchymosis—Methotrexate—esophageal cancer	0.000423	0.00264	CcSEcCtD
Amiodarone—Liver function test abnormal—Capecitabine—esophageal cancer	0.000421	0.00263	CcSEcCtD
Amiodarone—Pulmonary oedema—Methotrexate—esophageal cancer	0.000416	0.0026	CcSEcCtD
Amiodarone—CYP1A2—digestive system—esophageal cancer	0.000413	0.0153	CbGeAlD
Amiodarone—Visual impairment—Cisplatin—esophageal cancer	0.000413	0.00258	CcSEcCtD
Amiodarone—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000411	0.00257	CcSEcCtD
Amiodarone—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000411	0.00257	CcSEcCtD
Amiodarone—CYP1A1—digestive system—esophageal cancer	0.000407	0.015	CbGeAlD
Amiodarone—Muscular weakness—Capecitabine—esophageal cancer	0.000402	0.00251	CcSEcCtD
Amiodarone—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000402	0.00251	CcSEcCtD
Amiodarone—Tinnitus—Cisplatin—esophageal cancer	0.000399	0.00249	CcSEcCtD
Amiodarone—CYP3A5—digestive system—esophageal cancer	0.000398	0.0147	CbGeAlD
Amiodarone—Flushing—Cisplatin—esophageal cancer	0.000397	0.00248	CcSEcCtD
Amiodarone—Thrombophlebitis—Methotrexate—esophageal cancer	0.000392	0.00245	CcSEcCtD
Amiodarone—CYP2C9—digestive system—esophageal cancer	0.000392	0.0145	CbGeAlD
Amiodarone—Bronchospasm—Capecitabine—esophageal cancer	0.000388	0.00242	CcSEcCtD
Amiodarone—Photosensitivity—Methotrexate—esophageal cancer	0.000387	0.00242	CcSEcCtD
Amiodarone—Angina pectoris—Capecitabine—esophageal cancer	0.000384	0.0024	CcSEcCtD
Amiodarone—Arrhythmia—Cisplatin—esophageal cancer	0.000382	0.00239	CcSEcCtD
Amiodarone—Alopecia—Cisplatin—esophageal cancer	0.000378	0.00236	CcSEcCtD
Amiodarone—Hepatic failure—Methotrexate—esophageal cancer	0.000378	0.00236	CcSEcCtD
Amiodarone—Pancytopenia—Capecitabine—esophageal cancer	0.000374	0.00234	CcSEcCtD
Amiodarone—Erythema—Cisplatin—esophageal cancer	0.000373	0.00233	CcSEcCtD
Amiodarone—Neutropenia—Capecitabine—esophageal cancer	0.000369	0.0023	CcSEcCtD
Amiodarone—Renal failure acute—Methotrexate—esophageal cancer	0.000368	0.0023	CcSEcCtD
Amiodarone—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00036	0.00225	CcSEcCtD
Amiodarone—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00036	0.00225	CcSEcCtD
Amiodarone—Weight increased—Capecitabine—esophageal cancer	0.000359	0.00224	CcSEcCtD
Amiodarone—Visual disturbance—Methotrexate—esophageal cancer	0.000358	0.00224	CcSEcCtD
Amiodarone—Weight decreased—Capecitabine—esophageal cancer	0.000357	0.00223	CcSEcCtD
Amiodarone—Pneumonia—Capecitabine—esophageal cancer	0.000354	0.00221	CcSEcCtD
Amiodarone—Vision blurred—Cisplatin—esophageal cancer	0.000351	0.00219	CcSEcCtD
Amiodarone—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000351	0.00219	CcSEcCtD
Amiodarone—Tremor—Cisplatin—esophageal cancer	0.000349	0.00218	CcSEcCtD
Amiodarone—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000348	0.00218	CcSEcCtD
Amiodarone—SIGMAR1—lymph node—esophageal cancer	0.000346	0.0128	CbGeAlD
Amiodarone—Ill-defined disorder—Cisplatin—esophageal cancer	0.000346	0.00216	CcSEcCtD
Amiodarone—Renal failure—Capecitabine—esophageal cancer	0.000346	0.00216	CcSEcCtD
Amiodarone—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000345	0.00215	CcSEcCtD
Amiodarone—CYP1A2—lung—esophageal cancer	0.000345	0.0127	CbGeAlD
Amiodarone—Jaundice—Capecitabine—esophageal cancer	0.000343	0.00214	CcSEcCtD
Amiodarone—CYP1A1—lung—esophageal cancer	0.00034	0.0126	CbGeAlD
Amiodarone—Malaise—Cisplatin—esophageal cancer	0.000336	0.0021	CcSEcCtD
Amiodarone—CYP3A5—lung—esophageal cancer	0.000332	0.0123	CbGeAlD
Amiodarone—Agranulocytosis—Capecitabine—esophageal cancer	0.000328	0.00205	CcSEcCtD
Amiodarone—Bradycardia—Capecitabine—esophageal cancer	0.000321	0.00201	CcSEcCtD
Amiodarone—Ataxia—Methotrexate—esophageal cancer	0.000319	0.00199	CcSEcCtD
Amiodarone—Anxiety—Cisplatin—esophageal cancer	0.000316	0.00197	CcSEcCtD
Amiodarone—Hepatitis—Capecitabine—esophageal cancer	0.000316	0.00197	CcSEcCtD
Amiodarone—Liver function test abnormal—Methotrexate—esophageal cancer	0.000313	0.00196	CcSEcCtD
Amiodarone—Discomfort—Cisplatin—esophageal cancer	0.000313	0.00196	CcSEcCtD
Amiodarone—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000306	0.00191	CcSEcCtD
Amiodarone—Anaphylactic shock—Cisplatin—esophageal cancer	0.000304	0.0019	CcSEcCtD
Amiodarone—Oedema—Cisplatin—esophageal cancer	0.000304	0.0019	CcSEcCtD
Amiodarone—Visual impairment—Capecitabine—esophageal cancer	0.000304	0.0019	CcSEcCtD
Amiodarone—Infection—Cisplatin—esophageal cancer	0.000302	0.00189	CcSEcCtD
Amiodarone—CYP3A4—digestive system—esophageal cancer	0.000299	0.011	CbGeAlD
Amiodarone—Erythema multiforme—Capecitabine—esophageal cancer	0.000298	0.00186	CcSEcCtD
Amiodarone—Thrombocytopenia—Cisplatin—esophageal cancer	0.000298	0.00186	CcSEcCtD
Amiodarone—Tachycardia—Cisplatin—esophageal cancer	0.000297	0.00185	CcSEcCtD
Amiodarone—Skin disorder—Cisplatin—esophageal cancer	0.000295	0.00185	CcSEcCtD
Amiodarone—Tinnitus—Capecitabine—esophageal cancer	0.000294	0.00184	CcSEcCtD
Amiodarone—Hyperhidrosis—Cisplatin—esophageal cancer	0.000294	0.00184	CcSEcCtD
Amiodarone—CYP2D6—digestive system—esophageal cancer	0.000294	0.0109	CbGeAlD
Amiodarone—Flushing—Capecitabine—esophageal cancer	0.000293	0.00183	CcSEcCtD
Amiodarone—Eosinophilia—Methotrexate—esophageal cancer	0.000291	0.00182	CcSEcCtD
Amiodarone—Anorexia—Cisplatin—esophageal cancer	0.00029	0.00181	CcSEcCtD
Amiodarone—Pancreatitis—Methotrexate—esophageal cancer	0.000288	0.0018	CcSEcCtD
Amiodarone—Hypotension—Cisplatin—esophageal cancer	0.000284	0.00178	CcSEcCtD
Amiodarone—Arrhythmia—Capecitabine—esophageal cancer	0.000282	0.00176	CcSEcCtD
Amiodarone—Alopecia—Capecitabine—esophageal cancer	0.000279	0.00174	CcSEcCtD
Amiodarone—Pancytopenia—Methotrexate—esophageal cancer	0.000279	0.00174	CcSEcCtD
Amiodarone—ABCB1—epithelium—esophageal cancer	0.000278	0.0103	CbGeAlD
Amiodarone—KCNH2—lymph node—esophageal cancer	0.000275	0.0102	CbGeAlD
Amiodarone—Erythema—Capecitabine—esophageal cancer	0.000275	0.00172	CcSEcCtD
Amiodarone—Neutropenia—Methotrexate—esophageal cancer	0.000274	0.00171	CcSEcCtD
Amiodarone—Paraesthesia—Cisplatin—esophageal cancer	0.000273	0.00171	CcSEcCtD
Amiodarone—Dyspnoea—Cisplatin—esophageal cancer	0.000271	0.00169	CcSEcCtD
Amiodarone—Erectile dysfunction—Methotrexate—esophageal cancer	0.00027	0.00169	CcSEcCtD
Amiodarone—Dysgeusia—Capecitabine—esophageal cancer	0.000269	0.00168	CcSEcCtD
Amiodarone—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000268	0.00167	CcSEcCtD
Amiodarone—Back pain—Capecitabine—esophageal cancer	0.000266	0.00166	CcSEcCtD
Amiodarone—Decreased appetite—Cisplatin—esophageal cancer	0.000264	0.00165	CcSEcCtD
Amiodarone—Pneumonia—Methotrexate—esophageal cancer	0.000263	0.00164	CcSEcCtD
Amiodarone—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000263	0.00164	CcSEcCtD
Amiodarone—Pain—Cisplatin—esophageal cancer	0.00026	0.00162	CcSEcCtD
Amiodarone—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000259	0.00162	CcSEcCtD
Amiodarone—Vision blurred—Capecitabine—esophageal cancer	0.000259	0.00162	CcSEcCtD
Amiodarone—Tremor—Capecitabine—esophageal cancer	0.000257	0.00161	CcSEcCtD
Amiodarone—Renal failure—Methotrexate—esophageal cancer	0.000257	0.00161	CcSEcCtD
Amiodarone—Ill-defined disorder—Capecitabine—esophageal cancer	0.000255	0.00159	CcSEcCtD
Amiodarone—Sweating—Methotrexate—esophageal cancer	0.000251	0.00157	CcSEcCtD
Amiodarone—Feeling abnormal—Cisplatin—esophageal cancer	0.000251	0.00157	CcSEcCtD
Amiodarone—Malaise—Capecitabine—esophageal cancer	0.000248	0.00155	CcSEcCtD
Amiodarone—Vertigo—Capecitabine—esophageal cancer	0.000247	0.00154	CcSEcCtD
Amiodarone—ABCB1—trachea—esophageal cancer	0.000246	0.00908	CbGeAlD
Amiodarone—Agranulocytosis—Methotrexate—esophageal cancer	0.000244	0.00153	CcSEcCtD
Amiodarone—Body temperature increased—Cisplatin—esophageal cancer	0.00024	0.0015	CcSEcCtD
Amiodarone—Cough—Capecitabine—esophageal cancer	0.00024	0.0015	CcSEcCtD
Amiodarone—Hepatitis—Methotrexate—esophageal cancer	0.000235	0.00147	CcSEcCtD
Amiodarone—Anxiety—Capecitabine—esophageal cancer	0.000233	0.00146	CcSEcCtD
Amiodarone—CYP1A1—lymph node—esophageal cancer	0.000232	0.00859	CbGeAlD
Amiodarone—Discomfort—Capecitabine—esophageal cancer	0.000231	0.00144	CcSEcCtD
Amiodarone—Dry mouth—Capecitabine—esophageal cancer	0.000229	0.00143	CcSEcCtD
Amiodarone—Visual impairment—Methotrexate—esophageal cancer	0.000226	0.00141	CcSEcCtD
Amiodarone—Confusional state—Capecitabine—esophageal cancer	0.000226	0.00141	CcSEcCtD
Amiodarone—Oedema—Capecitabine—esophageal cancer	0.000224	0.0014	CcSEcCtD
Amiodarone—Hypersensitivity—Cisplatin—esophageal cancer	0.000224	0.0014	CcSEcCtD
Amiodarone—Infection—Capecitabine—esophageal cancer	0.000223	0.00139	CcSEcCtD
Amiodarone—Erythema multiforme—Methotrexate—esophageal cancer	0.000222	0.00139	CcSEcCtD
Amiodarone—Shock—Capecitabine—esophageal cancer	0.000221	0.00138	CcSEcCtD
Amiodarone—Thrombocytopenia—Capecitabine—esophageal cancer	0.00022	0.00137	CcSEcCtD
Amiodarone—Tinnitus—Methotrexate—esophageal cancer	0.000219	0.00137	CcSEcCtD
Amiodarone—Tachycardia—Capecitabine—esophageal cancer	0.000219	0.00137	CcSEcCtD
Amiodarone—Asthenia—Cisplatin—esophageal cancer	0.000218	0.00136	CcSEcCtD
Amiodarone—Skin disorder—Capecitabine—esophageal cancer	0.000218	0.00136	CcSEcCtD
Amiodarone—Hyperhidrosis—Capecitabine—esophageal cancer	0.000217	0.00135	CcSEcCtD
Amiodarone—Anorexia—Capecitabine—esophageal cancer	0.000214	0.00133	CcSEcCtD
Amiodarone—ABCB1—digestive system—esophageal cancer	0.000211	0.00781	CbGeAlD
Amiodarone—Hypotension—Capecitabine—esophageal cancer	0.000209	0.00131	CcSEcCtD
Amiodarone—Diarrhoea—Cisplatin—esophageal cancer	0.000208	0.0013	CcSEcCtD
Amiodarone—Alopecia—Methotrexate—esophageal cancer	0.000208	0.0013	CcSEcCtD
Amiodarone—Erythema—Methotrexate—esophageal cancer	0.000204	0.00128	CcSEcCtD
Amiodarone—Insomnia—Capecitabine—esophageal cancer	0.000203	0.00127	CcSEcCtD
Amiodarone—Paraesthesia—Capecitabine—esophageal cancer	0.000201	0.00126	CcSEcCtD
Amiodarone—Dysgeusia—Methotrexate—esophageal cancer	0.0002	0.00125	CcSEcCtD
Amiodarone—Dyspnoea—Capecitabine—esophageal cancer	0.0002	0.00125	CcSEcCtD
Amiodarone—Back pain—Methotrexate—esophageal cancer	0.000198	0.00124	CcSEcCtD
Amiodarone—Dyspepsia—Capecitabine—esophageal cancer	0.000197	0.00123	CcSEcCtD
Amiodarone—Decreased appetite—Capecitabine—esophageal cancer	0.000195	0.00122	CcSEcCtD
Amiodarone—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000194	0.00121	CcSEcCtD
Amiodarone—Vomiting—Cisplatin—esophageal cancer	0.000193	0.00121	CcSEcCtD
Amiodarone—Fatigue—Capecitabine—esophageal cancer	0.000193	0.00121	CcSEcCtD
Amiodarone—Vision blurred—Methotrexate—esophageal cancer	0.000193	0.0012	CcSEcCtD
Amiodarone—Rash—Cisplatin—esophageal cancer	0.000192	0.0012	CcSEcCtD
Amiodarone—Pain—Capecitabine—esophageal cancer	0.000192	0.0012	CcSEcCtD
Amiodarone—Constipation—Capecitabine—esophageal cancer	0.000192	0.0012	CcSEcCtD
Amiodarone—Dermatitis—Cisplatin—esophageal cancer	0.000192	0.0012	CcSEcCtD
Amiodarone—Ill-defined disorder—Methotrexate—esophageal cancer	0.00019	0.00119	CcSEcCtD
Amiodarone—Feeling abnormal—Capecitabine—esophageal cancer	0.000185	0.00115	CcSEcCtD
Amiodarone—Malaise—Methotrexate—esophageal cancer	0.000184	0.00115	CcSEcCtD
Amiodarone—Vertigo—Methotrexate—esophageal cancer	0.000184	0.00115	CcSEcCtD
Amiodarone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000183	0.00115	CcSEcCtD
Amiodarone—Nausea—Cisplatin—esophageal cancer	0.000181	0.00113	CcSEcCtD
Amiodarone—Cough—Methotrexate—esophageal cancer	0.000178	0.00111	CcSEcCtD
Amiodarone—Urticaria—Capecitabine—esophageal cancer	0.000178	0.00111	CcSEcCtD
Amiodarone—Body temperature increased—Capecitabine—esophageal cancer	0.000177	0.00111	CcSEcCtD
Amiodarone—Abdominal pain—Capecitabine—esophageal cancer	0.000177	0.00111	CcSEcCtD
Amiodarone—ABCB1—lung—esophageal cancer	0.000177	0.00653	CbGeAlD
Amiodarone—Discomfort—Methotrexate—esophageal cancer	0.000172	0.00107	CcSEcCtD
Amiodarone—Confusional state—Methotrexate—esophageal cancer	0.000168	0.00105	CcSEcCtD
Amiodarone—Anaphylactic shock—Methotrexate—esophageal cancer	0.000167	0.00104	CcSEcCtD
Amiodarone—Infection—Methotrexate—esophageal cancer	0.000166	0.00104	CcSEcCtD
Amiodarone—Hypersensitivity—Capecitabine—esophageal cancer	0.000165	0.00103	CcSEcCtD
Amiodarone—Thrombocytopenia—Methotrexate—esophageal cancer	0.000163	0.00102	CcSEcCtD
Amiodarone—Skin disorder—Methotrexate—esophageal cancer	0.000162	0.00101	CcSEcCtD
Amiodarone—Hyperhidrosis—Methotrexate—esophageal cancer	0.000161	0.00101	CcSEcCtD
Amiodarone—Asthenia—Capecitabine—esophageal cancer	0.000161	0.001	CcSEcCtD
Amiodarone—Anorexia—Methotrexate—esophageal cancer	0.000159	0.000994	CcSEcCtD
Amiodarone—Pruritus—Capecitabine—esophageal cancer	0.000159	0.000991	CcSEcCtD
Amiodarone—Hypotension—Methotrexate—esophageal cancer	0.000156	0.000974	CcSEcCtD
Amiodarone—Diarrhoea—Capecitabine—esophageal cancer	0.000153	0.000958	CcSEcCtD
Amiodarone—Insomnia—Methotrexate—esophageal cancer	0.000151	0.000943	CcSEcCtD
Amiodarone—Paraesthesia—Methotrexate—esophageal cancer	0.00015	0.000936	CcSEcCtD
Amiodarone—Dyspnoea—Methotrexate—esophageal cancer	0.000149	0.000929	CcSEcCtD
Amiodarone—Dizziness—Capecitabine—esophageal cancer	0.000148	0.000926	CcSEcCtD
Amiodarone—Dyspepsia—Methotrexate—esophageal cancer	0.000147	0.000918	CcSEcCtD
Amiodarone—Decreased appetite—Methotrexate—esophageal cancer	0.000145	0.000906	CcSEcCtD
Amiodarone—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000144	0.0009	CcSEcCtD
Amiodarone—Fatigue—Methotrexate—esophageal cancer	0.000144	0.000899	CcSEcCtD
Amiodarone—Pain—Methotrexate—esophageal cancer	0.000143	0.000892	CcSEcCtD
Amiodarone—Vomiting—Capecitabine—esophageal cancer	0.000143	0.00089	CcSEcCtD
Amiodarone—Rash—Capecitabine—esophageal cancer	0.000141	0.000883	CcSEcCtD
Amiodarone—Dermatitis—Capecitabine—esophageal cancer	0.000141	0.000882	CcSEcCtD
Amiodarone—Headache—Capecitabine—esophageal cancer	0.00014	0.000877	CcSEcCtD
Amiodarone—Feeling abnormal—Methotrexate—esophageal cancer	0.000138	0.000859	CcSEcCtD
Amiodarone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000136	0.000852	CcSEcCtD
Amiodarone—Nausea—Capecitabine—esophageal cancer	0.000133	0.000832	CcSEcCtD
Amiodarone—Urticaria—Methotrexate—esophageal cancer	0.000133	0.000828	CcSEcCtD
Amiodarone—Abdominal pain—Methotrexate—esophageal cancer	0.000132	0.000824	CcSEcCtD
Amiodarone—Body temperature increased—Methotrexate—esophageal cancer	0.000132	0.000824	CcSEcCtD
Amiodarone—Hypersensitivity—Methotrexate—esophageal cancer	0.000123	0.000768	CcSEcCtD
Amiodarone—ABCB1—lymph node—esophageal cancer	0.000121	0.00446	CbGeAlD
Amiodarone—Asthenia—Methotrexate—esophageal cancer	0.00012	0.000748	CcSEcCtD
Amiodarone—Pruritus—Methotrexate—esophageal cancer	0.000118	0.000738	CcSEcCtD
Amiodarone—Diarrhoea—Methotrexate—esophageal cancer	0.000114	0.000713	CcSEcCtD
Amiodarone—Dizziness—Methotrexate—esophageal cancer	0.00011	0.000689	CcSEcCtD
Amiodarone—Vomiting—Methotrexate—esophageal cancer	0.000106	0.000663	CcSEcCtD
Amiodarone—Rash—Methotrexate—esophageal cancer	0.000105	0.000657	CcSEcCtD
Amiodarone—Dermatitis—Methotrexate—esophageal cancer	0.000105	0.000657	CcSEcCtD
Amiodarone—Headache—Methotrexate—esophageal cancer	0.000105	0.000653	CcSEcCtD
Amiodarone—Nausea—Methotrexate—esophageal cancer	9.91e-05	0.000619	CcSEcCtD
Amiodarone—CYP3A5—Metabolism—CYP2A6—esophageal cancer	1.47e-05	9.54e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—CYP26A1—esophageal cancer	1.47e-05	9.52e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—CYP26A1—esophageal cancer	1.45e-05	9.43e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—TPI1—esophageal cancer	1.45e-05	9.39e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—GSTO1—esophageal cancer	1.45e-05	9.39e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—GNG7—esophageal cancer	1.44e-05	9.38e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—ALOX15—esophageal cancer	1.43e-05	9.27e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—ALDOB—esophageal cancer	1.42e-05	9.22e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—ALOX15—esophageal cancer	1.42e-05	9.19e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—CYP19A1—esophageal cancer	1.41e-05	9.16e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—NOTCH2—esophageal cancer	1.41e-05	9.15e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—HMOX1—esophageal cancer	1.4e-05	9.12e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—GSTT1—esophageal cancer	1.4e-05	9.11e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—ENO1—esophageal cancer	1.39e-05	9.04e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—PTGS1—esophageal cancer	1.39e-05	9.04e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—CYP2A6—esophageal cancer	1.39e-05	9.01e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—ALDOB—esophageal cancer	1.39e-05	9e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.38e-05	8.98e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CA1—esophageal cancer	1.38e-05	8.98e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.38e-05	8.97e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—PSME1—esophageal cancer	1.37e-05	8.91e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—PSME2—esophageal cancer	1.37e-05	8.91e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—GAPDH—esophageal cancer	1.37e-05	8.88e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—TPI1—esophageal cancer	1.36e-05	8.85e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—GSTO1—esophageal cancer	1.36e-05	8.85e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—CRABP1—esophageal cancer	1.35e-05	8.8e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—ALDH2—esophageal cancer	1.35e-05	8.79e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—GSTO1—esophageal cancer	1.35e-05	8.77e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—TPI1—esophageal cancer	1.35e-05	8.77e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—ABCB1—esophageal cancer	1.35e-05	8.76e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—ADH1B—esophageal cancer	1.34e-05	8.67e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—GAPDH—esophageal cancer	1.33e-05	8.66e-05	CbGpPWpGaD
Amiodarone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.33e-05	8.65e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—CRABP1—esophageal cancer	1.32e-05	8.59e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—PTGS1—esophageal cancer	1.31e-05	8.54e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—ENO1—esophageal cancer	1.31e-05	8.54e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—ALDOB—esophageal cancer	1.31e-05	8.48e-05	CbGpPWpGaD
Amiodarone—CACNA2D2—Metabolism—PIK3CA—esophageal cancer	1.3e-05	8.44e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—PSME1—esophageal cancer	1.3e-05	8.42e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—PSME2—esophageal cancer	1.3e-05	8.42e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.29e-05	8.41e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—GNG7—esophageal cancer	1.29e-05	8.37e-05	CbGpPWpGaD
Amiodarone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.29e-05	8.37e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—HMOX1—esophageal cancer	1.29e-05	8.36e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—GSTT1—esophageal cancer	1.29e-05	8.36e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—TYMP—esophageal cancer	1.28e-05	8.29e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—CYP2A6—esophageal cancer	1.27e-05	8.26e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.27e-05	8.23e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CA2—esophageal cancer	1.26e-05	8.21e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—GNG7—esophageal cancer	1.26e-05	8.17e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—GAPDH—esophageal cancer	1.26e-05	8.17e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—TGFBR2—esophageal cancer	1.25e-05	8.12e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.25e-05	8.09e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.25e-05	8.09e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.24e-05	8.06e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—ABCB1—esophageal cancer	1.24e-05	8.03e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.23e-05	8.02e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.21e-05	7.86e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—ALDH2—esophageal cancer	1.21e-05	7.84e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—PTGS1—esophageal cancer	1.21e-05	7.83e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—ENO1—esophageal cancer	1.21e-05	7.83e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—PSME2—esophageal cancer	1.19e-05	7.72e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—PSME1—esophageal cancer	1.19e-05	7.72e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—GNG7—esophageal cancer	1.18e-05	7.7e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—CYP1B1—esophageal cancer	1.18e-05	7.69e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—SMAD4—esophageal cancer	1.18e-05	7.68e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—ALDH2—esophageal cancer	1.18e-05	7.65e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.18e-05	7.63e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—ADH7—esophageal cancer	1.18e-05	7.63e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—GNG7—esophageal cancer	1.17e-05	7.63e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.15e-05	7.5e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—TPI1—esophageal cancer	1.15e-05	7.5e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—GSTT1—esophageal cancer	1.15e-05	7.46e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—CYP2A6—esophageal cancer	1.13e-05	7.37e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.13e-05	7.35e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.13e-05	7.34e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—GSTT1—esophageal cancer	1.12e-05	7.28e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—CYP1B1—esophageal cancer	1.12e-05	7.26e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—CYP19A1—esophageal cancer	1.11e-05	7.23e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—ALDH2—esophageal cancer	1.11e-05	7.21e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.11e-05	7.2e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.11e-05	7.19e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.1e-05	7.15e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—ENO1—esophageal cancer	1.08e-05	6.99e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PTGS1—esophageal cancer	1.08e-05	6.99e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.06e-05	6.92e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PSME1—esophageal cancer	1.06e-05	6.89e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PSME2—esophageal cancer	1.06e-05	6.89e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—GSTT1—esophageal cancer	1.06e-05	6.86e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—CRABP1—esophageal cancer	1.06e-05	6.86e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—CYP19A1—esophageal cancer	1.05e-05	6.83e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—ENO1—esophageal cancer	1.05e-05	6.82e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PTGS1—esophageal cancer	1.05e-05	6.82e-05	CbGpPWpGaD
Amiodarone—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.05e-05	6.82e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.05e-05	6.8e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1.04e-05	6.78e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.04e-05	6.74e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.03e-05	6.72e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PSME2—esophageal cancer	1.03e-05	6.72e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PSME1—esophageal cancer	1.03e-05	6.72e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.03e-05	6.7e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.03e-05	6.69e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—CYP1B1—esophageal cancer	1.02e-05	6.66e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—HMOX1—esophageal cancer	1.02e-05	6.6e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—GNG7—esophageal cancer	1e-05	6.52e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—ENO1—esophageal cancer	9.9e-06	6.43e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PTGS1—esophageal cancer	9.9e-06	6.43e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—TYMP—esophageal cancer	9.85e-06	6.4e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—ENO1—esophageal cancer	9.81e-06	6.37e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PTGS1—esophageal cancer	9.81e-06	6.37e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PSME1—esophageal cancer	9.75e-06	6.33e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PSME2—esophageal cancer	9.75e-06	6.33e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—ABCB1—esophageal cancer	9.74e-06	6.33e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—HIF1A—esophageal cancer	9.68e-06	6.29e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PSME2—esophageal cancer	9.67e-06	6.28e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PSME1—esophageal cancer	9.67e-06	6.28e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—CYP19A1—esophageal cancer	9.64e-06	6.26e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—HMOX1—esophageal cancer	9.59e-06	6.23e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CYP26A1—esophageal cancer	9.58e-06	6.22e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.41e-06	6.11e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—ALDH2—esophageal cancer	9.41e-06	6.11e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—ALOX15—esophageal cancer	9.33e-06	6.06e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	9.26e-06	6.01e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—KDR—esophageal cancer	9.26e-06	6.01e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—ABCB1—esophageal cancer	9.21e-06	5.98e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—CYP1B1—esophageal cancer	9.15e-06	5.94e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—CREBBP—esophageal cancer	9.01e-06	5.85e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—GSTT1—esophageal cancer	8.95e-06	5.81e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—CYP1B1—esophageal cancer	8.93e-06	5.8e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GSTO1—esophageal cancer	8.9e-06	5.78e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—TPI1—esophageal cancer	8.9e-06	5.78e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—CYP2A6—esophageal cancer	8.84e-06	5.74e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.81e-06	5.72e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—HMOX1—esophageal cancer	8.79e-06	5.71e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—NOTCH1—esophageal cancer	8.72e-06	5.66e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.63e-06	5.6e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—CYP19A1—esophageal cancer	8.6e-06	5.59e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—ALDOB—esophageal cancer	8.54e-06	5.55e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.44e-06	5.48e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—ABCB1—esophageal cancer	8.44e-06	5.48e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—CYP1B1—esophageal cancer	8.41e-06	5.47e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—CYP19A1—esophageal cancer	8.4e-06	5.45e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—ENO1—esophageal cancer	8.38e-06	5.45e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PTGS1—esophageal cancer	8.38e-06	5.45e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—CYP1B1—esophageal cancer	8.34e-06	5.42e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PSME1—esophageal cancer	8.26e-06	5.37e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PSME2—esophageal cancer	8.26e-06	5.37e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—CREBBP—esophageal cancer	8.26e-06	5.36e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GAPDH—esophageal cancer	8.22e-06	5.34e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CRABP1—esophageal cancer	8.14e-06	5.29e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—NOS3—esophageal cancer	8.07e-06	5.24e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—CYP19A1—esophageal cancer	7.91e-06	5.14e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	7.9e-06	5.13e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—HMOX1—esophageal cancer	7.85e-06	5.1e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—CYP19A1—esophageal cancer	7.84e-06	5.09e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	7.77e-06	5.05e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GNG7—esophageal cancer	7.75e-06	5.03e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.7e-06	5e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—HMOX1—esophageal cancer	7.66e-06	4.98e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—ABCB1—esophageal cancer	7.53e-06	4.89e-05	CbGpPWpGaD
Amiodarone—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	7.42e-06	4.82e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—NOS3—esophageal cancer	7.39e-06	4.8e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—PTGS2—esophageal cancer	7.38e-06	4.79e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—ALDH2—esophageal cancer	7.26e-06	4.72e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—HMOX1—esophageal cancer	7.22e-06	4.69e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.21e-06	4.69e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—HMOX1—esophageal cancer	7.16e-06	4.65e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—CYP1B1—esophageal cancer	7.13e-06	4.63e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—NOS3—esophageal cancer	7.08e-06	4.6e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.02e-06	4.56e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.96e-06	4.52e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—ABCB1—esophageal cancer	6.93e-06	4.5e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GSTT1—esophageal cancer	6.9e-06	4.49e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—ABCB1—esophageal cancer	6.87e-06	4.46e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CYP2A6—esophageal cancer	6.83e-06	4.43e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—PTGS2—esophageal cancer	6.76e-06	4.39e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	6.74e-06	4.38e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—CYP19A1—esophageal cancer	6.7e-06	4.35e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	6.62e-06	4.3e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—CREBBP—esophageal cancer	6.51e-06	4.23e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PTGS1—esophageal cancer	6.47e-06	4.2e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—ENO1—esophageal cancer	6.47e-06	4.2e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.38e-06	4.15e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PSME2—esophageal cancer	6.38e-06	4.14e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PSME1—esophageal cancer	6.38e-06	4.14e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—CREBBP—esophageal cancer	6.15e-06	4e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—EP300—esophageal cancer	6.14e-06	3.99e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—HMOX1—esophageal cancer	6.12e-06	3.97e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6e-06	3.9e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—ABCB1—esophageal cancer	5.87e-06	3.81e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—CCND1—esophageal cancer	5.85e-06	3.8e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—NOS3—esophageal cancer	5.83e-06	3.79e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.7e-06	3.7e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	5.66e-06	3.68e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—CREBBP—esophageal cancer	5.64e-06	3.66e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—EP300—esophageal cancer	5.62e-06	3.65e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—NOS3—esophageal cancer	5.51e-06	3.58e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CYP1B1—esophageal cancer	5.5e-06	3.57e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—EP300—esophageal cancer	5.38e-06	3.5e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—PTGS2—esophageal cancer	5.33e-06	3.46e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.19e-06	3.37e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CYP19A1—esophageal cancer	5.17e-06	3.36e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—NOS3—esophageal cancer	5.05e-06	3.28e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—PTGS2—esophageal cancer	5.04e-06	3.27e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—CREBBP—esophageal cancer	5.04e-06	3.27e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—CREBBP—esophageal cancer	4.91e-06	3.19e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.72e-06	3.07e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—MYC—esophageal cancer	4.69e-06	3.05e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—CREBBP—esophageal cancer	4.63e-06	3.01e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—PTGS2—esophageal cancer	4.62e-06	3e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—CREBBP—esophageal cancer	4.59e-06	2.98e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—EGFR—esophageal cancer	4.59e-06	2.98e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—PIK3CA—esophageal cancer	4.54e-06	2.95e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—ABCB1—esophageal cancer	4.53e-06	2.94e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—NOS3—esophageal cancer	4.51e-06	2.93e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.44e-06	2.88e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—EP300—esophageal cancer	4.44e-06	2.88e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—NOS3—esophageal cancer	4.4e-06	2.86e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—EP300—esophageal cancer	4.19e-06	2.72e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—PIK3CA—esophageal cancer	4.16e-06	2.7e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—NOS3—esophageal cancer	4.15e-06	2.69e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PTGS2—esophageal cancer	4.12e-06	2.68e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—NOS3—esophageal cancer	4.11e-06	2.67e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PTGS2—esophageal cancer	4.02e-06	2.61e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	3.98e-06	2.59e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.92e-06	2.55e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—TP53—esophageal cancer	3.85e-06	2.5e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—EP300—esophageal cancer	3.84e-06	2.5e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PTGS2—esophageal cancer	3.79e-06	2.46e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PTGS2—esophageal cancer	3.76e-06	2.44e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—NOS3—esophageal cancer	3.51e-06	2.28e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—EP300—esophageal cancer	3.43e-06	2.23e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—EP300—esophageal cancer	3.35e-06	2.17e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—PIK3CA—esophageal cancer	3.28e-06	2.13e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PTGS2—esophageal cancer	3.21e-06	2.09e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—EP300—esophageal cancer	3.15e-06	2.05e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—EP300—esophageal cancer	3.13e-06	2.03e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—PIK3CA—esophageal cancer	3.1e-06	2.01e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.03e-06	1.97e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—PIK3CA—esophageal cancer	2.84e-06	1.85e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—NOS3—esophageal cancer	2.71e-06	1.76e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—EP300—esophageal cancer	2.67e-06	1.74e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PIK3CA—esophageal cancer	2.54e-06	1.65e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.48e-06	1.61e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.48e-06	1.61e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.33e-06	1.52e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.31e-06	1.5e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—EP300—esophageal cancer	2.06e-06	1.34e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.98e-06	1.28e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.53e-06	9.91e-06	CbGpPWpGaD
